^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Kanjinti (trastuzumab-anns) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/13/2019
Excerpt:
KANJINTI is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of
patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have
not received prior treatment for metastatic disease.
Secondary therapy:
FP; XP
Source:
Title:
Study of chemotherapy combined with ABP 980 in patients with advanced cancer of stomach or gastro-esophageal junction HER2-positive Studio di chemioterapia associata ad ABP 980 in pazienti con tumore dello stomaco o della giunzione gastro-esofagea avanzato HER2 positivo
Excerpt:
...Tumor HER2 overexpressing, as determined by local testing on a gastric or GEJ tumor specimen. ...
Trial ID:
